SELLAS Life Sciences (SLS)

• Market cap: $1.51B
• 1 day: 4.37%
• 5 days: 13.25%
• 1 month: 66.39%
• 3 months: 65.04%
• 6 months: 456.16%
• Year to date: 86.67%
• 1 year: 320.73%
• 5 years: -20.7%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Employees: 13